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Although virtually all of the 400,000 coronary bypass
surgeries performed in the U.S. each year use at least one
arterial graft conduit (internal mammary or free radial),
most still involve the placement of one or more saphenous
vein grafts. These grafts immediately begin to develop
intimal hyperplasia in response to surgical trauma, a loss of
intrinsic vascular supply, and exposure of the thin-walled
structure to an abrupt increase in wall stress as it is moved
from the low-pressure venous to the high-pressure arterial
environment. This sets the stage for subsequent atheroscle-
rotic degeneration and superimposed thrombus, causing
more than 50% of these grafts to fail by seven years after
surgery and accounting (along with progressive native cor-
onary disease) for late recurrent angina in this patient
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population. Given the risk of injuring other patent grafts
and the generally higher risk of re-operation in an older and
sicker patient population, percutaneous treatment of failing
saphenous vein grafts is generally preferred (1) and accounts
for some 10% to 15% of coronary intervention in most
centers. But these interventions present several unique
challenges based on the soft and friable nature of the
degenerated vein graft lesion, the tendency for distal athe-
roembolization to produce peri-procedural no-reflow and
myocardial infarction (MI), the frequent association or large
thrombi superimposed on critical graft stenosis or recent
occlusion, and the high long-term recurrence rate (due to
both restenosis at the target site and progression of disease at
other sites to cause target vessel failure). Given these
multiple challenges, it is natural that catheter management
of the diseased saphenous vein graft has been the subject of
multiple device development strategies. Although some
progress has been made (2), short- and long-term results
remain far worse than those of native vessel intervention (3).
The core interventional technology is, as in other vascular
territories, stent placement. The predictable ability of bare
metal stent placement to provide a large and smooth
vascular lumen has made stenting the default interventional
modality in the diseased saphenous vein graft. Despite the
limited nature of the original randomized trials in this area
(with rapid adoption of stenting in the mid-1990s and the
subsequent reluctance of operators to randomize patients to
conventional balloon angioplasty), balloon expandable and,
to a lesser extent, self-expanding stents are used in virtually
every graft intervention. Stent placement may be performed
after balloon pre-dilation or directly when the graft and
lesion anatomy are favorable. If large associated luminal
thrombi are present, thrombectomy with the Possis Angio-
Jet rheolytic thrombectomy catheter (Possis Medical Inc.,
Minneapolis, Minnesota) has been shown to be superior to
overnight infusion of a thrombolytic agent (4). The Endi-
COR X-Sizer catheter (ev3, Plymouth, Minnesota) has
recently shown benefit in reducing large MIs in thrombotic
saphenous vein grafts despite its failure in reducing the
overall prespecified 30-day composite death, MI, urgent
revascularization end point (5). Newer ultrasonic thrombec-
tomy devices also are just entering clinical testing.
Whether or not thrombus is present, a large part of the
acute complications of saphenous vein graft intervention
stems from the compromise of the distal (arteriolar) myo-
cardial microcirculation, evident as peri-procedural MI
(17% to 20% of procedures) (6), or the no-reflow phenom-
enon (8% of procedures) (7). For most of the 1990s, these
complications were felt to result from spasm of these vessels
induced by serotonin or other vasoconstrictors and treated
accordingly with small vessel vasodilators (calcium channel
blockers, nitroprusside, or adenosine), with encouraging but
imperfect results. The other causative candidate was platelet
aggregation, but clinical trials have shown no benefit of
platelet glycoprotein IIb/IIIa receptor blockers in this lesion
type (8). The problem has been clarified significantly by the
introduction of distal embolic protection devices, such as the
PercuSurge distal occlusion GuardWire (Medtronic AVE,
Santa Rosa, California), whose 801-patient Saphenous Vein
Graft Angioplasty Free of Emboli Randomized trial (9)
demonstrated a significant reduction in both 30-day adverse
events (from 17% to 9.6%) and the no-reflow phenomenon
(from 8.3% to 3.3%), compared with stenting performed
over a conventional guidewire. More recently, the distal
Boston Scientific/EPI FilterWire (Natick, Massachusetts)
has shown equivalence (noninferiority) to the GuardWire in
the 651-patient FIRE trial (10). Several other distal filter
devices and two devices for proximal occlusion (which allow
emboli to be collected into the guiding catheter) are now
under study for this indication. To date, however, none of
the embolic protection devices have been able to totally
eliminate the distal embolic risk in this challenging patient
subset and bring the adverse clinical even rate below 9% in
a high-risk cohort.
Aside from acute procedure safety, percutaneous vein
graft treatment is frustrated by the fact that a larger
proportion (35% to 40% vs. 20% to 25%) of treated
saphenous vein grafts fail over the next 12 to 18 months
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compared with treated native vessels. About one-half of
those failures represent restenosis of the stented site and the
other half represent failure of the treated vessel because of
progression of subclinical disease elsewhere that the original
stented lesion (11,12). With current stents, operators are
understandably reluctant to minimize this latter failure
mode by “relining” the entire graft because of the penalty of
increasing restenosis risk with increasing stent length. Be-
cause the mechanism of in-stent restenosis in vein grafts is
also neointimal hyperplasia and the response of in-stent
restenosis to brachytherapy is similar (13), one may hope for
a similar benefit from antiproliferative drug-eluting stents to
that seen in native vessels, but studies of such drug-eluting
stents in vein grafts are not yet available.
Developing in parallel with distal protection devices,
thrombectomy, and drug-eluting stents, another approach
to both distal embolization and restenosis in saphenous vein
grafts are membrane-covered stents that hopefully would
trap friable plaque against the graft wall and reduce the
degree of subsequent neointimal proliferation inside the
stent. Despite some early registry data to that effect (14), the
larger randomized trials are beginning to show a consistent
lack of benefit in either regard. That is certainly the case for
the 211-patient multicenter STents IN Grafts (STING)
trial, which was conducted in late 1999 and throughout
2000, and is reported in this issue of the Journal by
Scha¨chinger et al. (15). In STING, patients underwent
treatment of lesions between 5 and 45 mm in length in
10-year-old grafts with an average reference diameter of 3.4
mm, randomized at 12 German and Austrian sites to
undergo placement of either a conventional metal Jomed
Flex Stent (Helsingborg Sweden) or the hand-mounted
Jomed StentGraft, which consists of a layer of polytetra-
fluoroethylene sandwiched between an inner and an outer
metallic stent. Both devices are available in multiple lengths
(9, 16, and 26 mm). Although the additional material makes
the StentGraft somewhat stiffer to deliver and harder to
expand fully (note the maximum deployment pressure of
16.4 vs. 15.0 atms for the StentGrafts), it was delivered
successfully in all but 3 of the 102 patients assigned to the
StentGraft group. We were not told the lesion length, but
the total stent length of 19 mm (representing 1.2 stents per
lesion) and residual stenosis (4.5% vs. 6.6%) were compa-
rable with those in patients assigned to the bare FlexStent.
This study thus constitutes a fair test of the Jomed Stent-
Graft in typical vein grafts.
Although the study details do not describe how this was
ascertained, there was no evidence of reduced distal embo-
lization. Of note, the 5.6% and 4.9% MI rates reported in
the two arms of STING are far below the 15% or greater
rates in the literature. This was not due to liberal use of
distal embolic protection devices (10% of both groups)
and more likely reflects the use of a non-standard enzyme
criterion for MI (creatine kinase [CK] 3 times normal),
rather than the more standard (total CK 2 times normal
or CK-MB fraction 3 times normal as used in SAFER).
A low event rate in the control arm could also reflect
treatment of “low-risk” graft lesions because we have yet to
develop a robust model that predicts unprotected event rates
in vein graft stent patients as a function of lesion length and
extent of overall graft degeneration. But the lack of evident
embolic protection by the covered stent in STING is
consistent with the preliminary data from RECOVERS
(16). That 301-patient Italian trial was similar in design
except for lower use of IIb/IIIa blockers (15%) but showed
significantly more periprocedural MIs and six-month cu-
mulative major adverse clinical events with the covered as
opposed to bare metal stent. This likely reflects dislodge-
ment of emboli during advancement of the relatively rigid
device, or a “toothpaste” effect by which material is squeezed
from the center to the ends of the lesion, allowing it to
escape from the covered area. Final confirmation will come
from the large U.S. BARRICADE trial, which is still in
active enrollment, but even increased embolization would
not be lethal to this strategy if the covered stents were
deployed over an embolic protection device.
However, the primary end point of STING was the
ability of the StentGraft to reduce six-month angiographic
restenosis. The performance of the bare FlexStent was
better than expected, with late loss of 0.95 mm and a 20%
angiographic restenosis, nearly one-third (7%) of which
represented total occlusion. The low restenosis rate may
indicate favorable baseline clinical factors in the trial as a
whole or simply the play of chance, but could also reflect the
use of an earlier angiographic restudy time-point than the 8
to 12 months used in some other graft trials. However, if
anything, the performance of the covered StentGraft was
worse than a bare metal stent, with a late loss of 1.17 mm
and a restenosis rate of 29%, one-half (16%) of which
represented late occlusion. This is even more disappointing
than the RECOVERS data, where the StentGraft group
had an unchanged 24% restenosis, half of which (11% to
12%) represented late occlusion.
It is not clear how many of these late occlusions in
STING were just the result of intense in-stent proliferation
rather than subacute thrombosis, but the antithrombotic
regimen (heparin and abciximab intraprocedure and a thien-
opyridine for three months after stent placement) was
standard. Acute thrombosis is the presumed culprit in one
early (2 day) and one late (125 day) occlusion of a Stent-
Graft accompanied by abrupt chest pain and CK elevation
but is not excluded by absence of these markers in the 11
remaining StentGraft occlusions. Nor do we know whether
the period required for complete endothelialization of this
composite device is as short as the two- to four-week period
reported for bare metal stents, or more like the eight-plus
month period seen when a new metallic stent is placed in
conjunction with brachytherapy. Certainly clinical users of
this device, which is marketed in Europe and the U.S.
(under a Humanitarian Device Exemption for the treatment
of coronary perforation) might well consider prolonging the
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duration of clopidogrel treatment to eight months to min-
imize this risk.
The STING trial also raises issues relating to the pre-
specified 12-month clinical end points, which include death,
MI (using the CK 3 times the normal cutoff), and target
lesion revascularization (TLR). Death (8.8% vs. 5.8%) and
MI (9.8% vs. 7.7%) were nonsignificantly higher with the
StentGraft, but repeat TLR revascularization was nonsig-
nificantly lower (17% vs. 21% for the target lesion and 20%
vs. 24% for the target vessel). That difference in TLR was
thus an important contributor to achieving a similar com-
posite clinical event rate (31% vs. 31%) at 12 months.
However, in the face of higher angiographic restenosis and
total occlusion, this lower TLR rate reflects more a reluc-
tance of operators to proceed to reintervention in an
occluded graft (only four of the StentGraft occlusion un-
derwent such reintervention) rather than a measure of
long-term clinical benefit. Had a broader end point of target
vessel failure been used, the performance of the StentGraft
might have been demonstrated to be significantly worse
than the bare FlexStent.
WHERE DO WE STAND?
At this point, the best treatment for a degenerated stenotic
saphenous vein graft is probably bare metal stenting of the
stenotic segment performed in association with distal em-
bolic protection. If a large associated thrombus is present,
this should be preceded by mechanical thrombectomy (pos-
sibly over the shaft of the embolic protection device). Once
large-diameter drug-eluting stents are available (and their
benefit in saphenous vein grafts is established) they will
likely be substituted for bare metal stents, with concomitant
reduction in restenosis. This would also enable us to treat
preemptively longer graft segments, in an effort to reduce
late failures due to rapid progression of moderate disease.
But based on the available data from STING and RECOV-
ERS, the Jomed StentGraft provides no additional benefit
against either distal embolization or restenosis. Therefore,
barring distinctly different data from the pending BARRI-
CADE trial using this device or positive data from trials of
the Boston Scientific self-expanding Symbiot covered stent,
the use of covered stents under the current Humanitarian
Device Exemption should probably be reserved for the
covered indications of vessel perforation and local aneu-
rysms. We should not rule out the possibility that future
composite stent grafts could be treated with compounds that
would resist proliferation or encourage functional endothe-
lial coverage. Even if trials show significant benefit against
bare metal stents, however, they will also have to demon-
strate benefit over drug-eluting stents. Although we are
clearly making progress, the ultimate solution to the percu-
taneous management of diseased saphenous vein graft is
thus still under development!
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